Finecare™ 2019-nCoV Antigen Test Antigen testing indicates the active infection of 2019-nCoV. For areas with limited PCR resources, antigen testing can be used for aiding in the diagnosis of COVID-19 suspect patients.

Intended Use Covid 19 Ag Card Test is designed for in vitro qualitative detection of Covid 19 antigen in human nasopharyngeal, nasal swab specimens. The kit is intended for professional use and as a screening test and is an aid in early diagnosis of SARS COV-2 infection in patients with clinical symptoms. Salient Features Rapid Visual Test for the Qualitative Detection of Covid-19 (SARS-COV-2) antigen in Human nasopharyngeal and nasal swab specimens. Based on Sandwich Immunoassay principle. Results within 20 minutes. Single step test procedure. Evaluated & Validated by ICMR Centre ; Sensitivity -91.5% (<30 CT) & Specificity -100% against RT-PCR. Long Shelf life:30 months at 2-30° C. No Instruments required. Convenient pack sizes . 10T,25T,50T,100T & 200T.

Buy AccuTest COVID-19 IgG/IgM Rapid Test (Pack of 10 Tests) Online. COVID-19 IgG/IgM Rapid Test Kit is a qualitative immuno chromatographic assay for the detection of IgG & IgM antibodies produced against COVID-19 virus in human whole blood/Serum/ Plasma. COVID-19 IgG/IgM Rapid Test Kit is only intended for initial screening and reactive samples should be confirmed by a supplemental assay. Intended Use: COVID-19 IgG/IgM Rapid Test Kit is a qualitative immuno chromatographic assay for the detection of IgG & IgM antibodies produced against COVID-19 virus in human whole blood/Serum/ Plasma. COVID-19 IgG/IgM Rapid Test Kit is only intended for initial screening and reactive samples should be confirmed by a supplemental assay. SUMMARY & TEST DESCRIPTION: COVID-19 [Coronavirus Disease- 2019] is an infectious disease caused by SARS-CoV2 [Severe Acute Respiratory Syndrome coronavirus 2] virus, which is a contagious, novel strain of CoronaVirus that emerged from Wuhan, China in December 2019, which grew as a pandemic threatening human survival across the globe. The virus is thought to be of zoonotic origin and likely to have spread from large seafood and animal markets by human-animal contact in the city of Wuhan, where consumption of such products is in large. The virus causes respiratory infection with symptoms including fatigue, fever, shortness of breath, respiratory failure, renal failure and death. Patients can become infected with SARS-CoV-2 virus by person-person contact (through contact with a contaminated environment or person). The young and old (and other immune-compromised individuals) are most at risk of serious complications; however, approximately 20% of those infected can develop a critical condition. COVID-19 IgG/IgM Rapid Test device utilizes Anti-human IgG and Anti-human IgM antibodies as the capture molecules. COVID-19 Recombinant Antigens-colloidal gold conjugate are used as detection antigen. Intended Use: COVID-19 IgG/IgM Rapid Test Kit is a qualitative immuno chromatographic assay for the detection of IgG & IgM antibodies produced against COVID-19 virus in human whole blood/Serum/ Plasma. COVID-19 IgG/IgM Rapid Test Kit is only intended for initial screening and reactive samples should be confirmed by a supplemental assay. SUMMARY & TEST DESCRIPTION: COVID-19 [Coronavirus Disease- 2019] is an infectious disease caused by SARS-CoV2 [Severe Acute Respiratory Syndrome coronavirus 2] virus, which is a contagious, novel strain of CoronaVirus that emerged from Wuhan, China in December 2019, which grew as a pandemic threatening human survival across the globe. The virus is thought to be of zoonotic origin and likely to have spread from large seafood and animal markets by human-animal contact in the city of Wuhan, where consumption of such products is in large. The virus causes respiratory infection with symptoms including fatigue, fever, shortness of breath, respiratory failure, renal failure and death. Patients can become infected with SARS-CoV-2 virus by person-person contact (through contact with a contaminated environment or person). The young and old (and other immune-compromised individuals) are most at risk of serious complications; however, approximately 20% of those infected can develop a critical condition. COVID-19 IgG/IgM Rapid Test device utilizes Anti-human IgG and Anti-human IgM antibodies as the capture molecules. COVID-19 Recombinant Antigens-colloidal gold conjugate are used as detection antigen. PRECAUTIONS & WARNING 1. This package insert must be read completely before performing thetest. Failuretofollow directions in insert may yield inaccurate test results. 2. Test results should be read between 10 and 15 minutes after aspecimenisapplied to the sample well. Results read after 20 minutes may giveerroneousresults.3. Do not open the sealed pouch until you are ready to conduct theassay.Onceopened, the cassettes should be used immediately. 4. Do not use expired devices. 5. Bring all reagents to room temperature (15-30°C) prior to use. 6. Do not mix components from different kits. Use only the buffer suppliedalongwith the kit. 7. Wear protective clothing and disposable gloves while handling thekit reagentsand clinical specimens. Wash hands thoroughly after performing thetest. 8. Do not smoke, drink, or eat in areas where specimens or kit reagents arebeinghandled. 9. Dispose of all specimens and materials used to performthe test as biohazardouswaste. 10. Handle the negative and positive controls in the same manner as patientspecimens for operator protection. 11. Do not perform the test in a room with strong air flow, i.e. an electricfanorstrong air-conditioning. 12. Do not touch result window. 13. Use only for in-vitro diagnostic purpose.

STANDARD Q COVID-19 Ag STANDARD Q COVID-19 Ag Test is a rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigens to SARS-CoV-2 present in human nasopharynx

INTENDED USE The Finecare™ 2019-nCoV lgM/lgG Test is a fluorescence immunoassay used along with Finecare™ FIA Meters for qualitative detection of IgG and IgM antibodies of novel coronaviruses (2019-nCoV) in human whole blood, serum and plasma specimen. Clinically, the test is to be used as an aid in the diagnosis of coronavirus infection disease (COVID-19), which is caused by 2019-nCoV. The test provides preliminary test results. Negative results cannot exclude the possibility of 2019-nCoV infection and they cannot be used as the sole basis for treatment or other management decision. STORAGE AND STABILITY 1. Store at 4-30°C in the sealed pouch up to the expiration date printed on the package. Do not freeze. 2. The test device should be used within 1 hour after taking out from the foil envelope. 3. Keep away from sunlight, moisture and heat. 4. Kit contents are stable until the expiration date printed on the outer box.

The advanced BC-6800Plus not only provides more reliable routine CBC plus 5-part DIFF results, but also has a higher throughput of up to 200 samples per hour. Based on the new SF Cube technology platform, the BC-6800Plus could provide more reliable blood cell results and abnormal cells flagging results with anticipated warning messages, exceeding clinicians’ expectations and setting a new standard for blood analysis. SF Cube Technology With the newly designed opticals and reagent systems, the SF Cube technology can help doctors to better differentiate the clusters of cells, which is the key to revealing more abnormal cells. NRBC result in every CBC In WNB scattergram, BC-6800Plus provides NRBC, Basophils and WBC-N* results. It means that the actual number of NRBCs can be measured in routine CBC, if they are present in the sample. Basophils are counted in this counting channel with NRBC results. Basophil and NRBC results are generated on BC-6800Plus without extra reagent or cost. NLR parameter in each CBC+DIFF Neutrophil-to-lymphocyte ratio (NLR) is calculated by dividing neutrophil count by lymphocyte count, usually from peripheral blood sample. In laboratory medicine, NLR is used as a marker of subclinical inflammation. According to clinical studies, NLR can be used as a prognostic factor of severe illness in COVID-19 patients. More accurate RET and PLT-O result By utilizing the new fluorescent dye, the reticulocytes and platelets are more specific stained with stronger fluorescent signal, that brings more reliable reticulocyte and platelet results. Automatic Rerun & Reflex Should the sample results trigger the criteria, the sample rack can automatically step back for a “rerun” or “reflex” check. 200 test/hour BC-6800Plus can load up to 100 samples at a time and offers a throughput of up to 200 tests per hour.

Based on Mindray’s continuous innovation in hematology field, BC-5130 is especially tailored to assist diagnostic labs who need full CBC + 5-part results, with relatively low daily sample volume, restricted lab space and tight budget. As the lightest and most compact 5-part hematology analyzer so far from Mindray, BC-5130 is a highly user-friendly and innovative analyzer that offers cost efficient CBC and 5-part white cell differential results. It is targeted to fulfill and exceed the demands of our global customers by providing more accurate, more efficient and more innovative solutions for labs. Improved DC impedance technology is used to count and size the RBC and PLT. The smaller counting aperture (50 μm in diameter) provides better performance on samples with low PLT. Efficient Only three routine reagents are required. These have 2 years shelf life and also less consumed by BC-5130. Original QC and calibrator are also provided to ensure the hematology analyzer’s traceability and testing quality. WBC 5-Part differentiation,25 reportable parameters & 23 research parameters,3 histograms Whole blood Mode, Capillary whole blood mode & Prediluted Mode Tri-angle Laser Scatter + Chemical dye + Flow cytometry technology Dedicated optical counting channel for Basophil measurement 10.4 inch large TFT touch screen with user-friendly software Large storage capacity: Up to 1,50,000 samples Throughput:60 samples/Hour Compact Two kinds of lyse reagents are located inside of BC-5130, which helps the small labs to save space. BC-5130, the 5-part hematology analyzer offers a great solution for clinical labs, especially for those who have limited space. Its compact foot-print is a result of innovative technology improvements, including miniaturized semi-conductor laser source, highly integrated electronic boards and optimized liquid handling system. BC-5130 inherits it’s convenient and proven powerful software design from BC-6800 and BC-3600 platforms, the friendly interface is ideal for small sized labs. Running capillary blood through the sample probe directly is more convenient for the users in children’s hospitals, etc. For Prediluted mode, BC-5130 has higher dilution ratio than other 5-part hematology There’s NLR parameter in each CBC+DIFF result. Neutrophil-to-lymphocyte ratio (NLR) is calculated by dividing neutrophil count by lymphocyte count, usually from peripheral blood sample. In laboratory medicine, NLR is used as a marker of subclinical inflammation. According to clinical studies, NLR can be used as a prognostic factor of severe illness in COVID-19 patients. BC-5130 supports bi-directional LIS with test results and patient information. HL7 protocol is supported as well. Technology Compared with traditional helium neon laser or argon laser, semi -conductor laser has smaller size, lower cost and longer life cycle.

The STANDARD Q COVID/Flu Ag Combo Test is a rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2 and Influenza A and Influenza B present in human nasopharyngeal specimens. The STANDARD Q COVID/Flu Ag Combo Test for rapid detection of SARS-CoV-2, Influenza A and Influenza B is a differentiated test, such that SARS-CoV-2 viral antigens can be distingushed from Influenza A or Influenza B viral antigens from a single specimen using a single device.

INTENDED USE The Finecare™ 2019-nCoV RBD Antibody Test is a fluorescence immunoassay used along with Finecare™ FIA Meters for qualitative and semi-quantitative detection of spike receptor-binding domain (RBD) antibodies of novel coronaviruses (2019-nCoV) in human fingerstick whole blood, venipuncture whole blood, serum or plasma specimen. The 2019-nCoV RBD antibodies are protective antibody produced by the human body after inoculation with 2019-nCoV vaccine or infection with 2019-nCoV. The test is intended as an aid to assess the adaptive humoral immune response to the 2019-nCoV RBD protein. STORAGE AND STABILITY 1. Store at 4~30°C in the sealed pouch up to the expiration date printed on the package. Do not freeze. 2. The test device should be used within 1 hour after taking out from the foil envelope. 3. Keep away from sunlight, moisture and heat. 4. Kit contents are stable until the expiration date printed on the outer box.